Mannatech results
This article was originally published in The Tan Sheet
Executive Summary
Firm's net sales increase 7.6% to $58.4 mil., with earnings up 118.8% to $3.1 mil. in the first quarter (ended March 31). Mannatech attributes the results to "building momentum" from new and existing associates and members. The firm's sales associates brought 141,000 new customers in the 12 months ended March 31, according to CEO Samuel Caster. Mannatech plans to launch products in South Korea in the third quarter and roll out Ambrotose AO in the United Kingdom, Japan, Australia and New Zealand later this year...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.